the only retractable syringe on the market 25 gauge 1 inch needle for activating immediately and completely shields the used needle, quickly eliminating the risk of exposure to a needlestick injury
BPC-157 and TB-500 work through different but complementary mechanisms: BPC-157 focuses on localised healing, tissue repair, and reducing inflammation TB-500 promotes systemic recovery, flexibility, and cell migration to injured areas When combined, they create a more complete recovery environment than either peptide used alone
1,2,6 Neurologic manifestations are caused by progressive demyelination and can include peripheral neuropathy, areflexia, and the loss of proprioception and vibratory sense
Antimicrob Agents Chemother.Feb 2016;60(2):968-981
Our proposed clinical dose of BPC157 was 200 g/person/day, and its equivalent dose in rats was 20 g/kg (converted based on body surface area)